Key result
Optical genome mapping combined with next-generation sequencing achieved an overall diagnostic yield of 58% for identifying facioscapulohumeral muscular dystrophy types 1 and 2.
Why the study?
The study was conducted to validate the optical genome mapping (OGM) platform for accurate mapping of the D4Z4 repeat size and evaluate diagnostic testing in patients with clinically suspected FSHD.
Does optical genome mapping combined with next-generation sequencing accurately diagnose Facioscapulohumeral muscular dystrophy in clinically suspected patients?
Observational (n=547)
Does optical genome mapping combined with next-generation sequencing accurately diagnose Facioscapulohumeral muscular dystrophy in clinically suspected patients?
Optical genome mapping combined with next-generation sequencing provides a practical and precise method for diagnosing FSHD types 1 and 2, achieving a 58% diagnostic yield in suspected cases.
No takes yet. Share an insight, caveat, or question.
Supports OGM plus NGS for FSHD diagnosis in suspected cases; leaves open broader validation before routine adoption.
Guruju et al. (2023) conducted an observational in Facioscapulohumeral muscular dystrophy (FSHD) (n=547). Optical genome mapping (OGM) and next-generation sequencing (NGS) vs. Southern blot-based diagnosis was evaluated on Overall diagnostic yield. Optical genome mapping combined with next-generation sequencing achieved an overall diagnostic yield of 58% for identifying facioscapulohumeral muscular dystrophy types 1 and 2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: